Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.

about

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.

Item

http://www.wikidata.org/entity/Q41282858

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Spotlight on glycopyrronium/fo ...... lopment, and place in therapy.

@en

type

Item

label

Spotlight on glycopyrronium/fo ...... lopment, and place in therapy.

@en

prefLabel

Spotlight on glycopyrronium/fo ...... lopment, and place in therapy.

@en

P1476

Spotlight on glycopyrronium/fo ...... lopment, and place in therapy.

@en

P2093

Gerard J Criner

http://www.w3.org/2001/XMLSchema#string

Santosh Dhungana

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Projections of global mortality and burden of disease from 2002 to 2030

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease.

Effects of formoterol inhaled dry powder on exercise performance in chronic obstructive pulmonary disease: a single-center, randomized, double-blind, placebo-controlled, crossover study.

Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.

Tiotropium Respimat inhaler and the risk of death in COPD.

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial

P304

2307-2312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/COPD.S89482

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28814858

http://www.w3.org/2001/XMLSchema#string

P921

aerosol

Alcoal

amine

chronic obstructive pulmonary disease

mechanism of action

onium ion

Anagraw amesgunef

P932

5546727

http://www.w3.org/2001/XMLSchema#string